Shiyi Investment

Shiyi Investment

Shiyi Investment was established in Shanghai in 2015 by Lin Lijun, who brought a research-first sensibility to a market then dominated by volume-driven venture strategies. The firm launched to capture early-stage opportunities emerging from China’s shift toward indigenous enterprise technology and healthcare innovation, a structural tailwind that accelerated as policy and commercial pressures favored domestic suppliers. Lin structured the firm as an independent asset manager rather than a corporate venture arm or a family office vehicle, positioning it to raise discretionary capital from institutional limited partners. The firm targets seed and Series A rounds across enterprise software, artificial intelligence, digital health, and industrial technology. Its portfolio construction favors concentrated positions — typically 15 to 25 active investments at any time — with reserve allocation for follow-on participation through Series B. Publicly reported portfolio companies include AI-driven drug discovery platform Xbiome and industrial robotics developer Mech-Mind Robotics, though the full portfolio remains largely private. Shiyi co-invests alongside domestic Chinese venture funds like Qiming Venture Partners and Sequoia Capital China on select deals, suggesting a syndication network that augments its own sourcing. Geographic focus centers on Shanghai, Beijing, and Shenzhen, where the bulk of China’s foundational tech startups cluster. Shiyi maintains a compact investment team led by Lin Lijun and a cohort of sector-specialist partners with backgrounds in computer science and life sciences. The firm does not publicly report assets under management or total deployment. In 2023, Shiyi participated in Xbiome’s Series B extension (per public record), confirming continued capital deployment into AI-enabled life sciences despite broader venture market contraction in China. The firm has not disclosed adjacent philanthropic structures, club memberships, or real-asset arms, and its operational footprint appears limited to its Shanghai headquarters. Shiyi’s structural differentiator is its research bench: the firm embeds technical PhD-level analysts within diligence teams, a model more common to deep-tech hedge funds than to typical early-stage venture managers in China. This architecture allows it to evaluate frontier technologies — AI-native drug discovery, autonomous industrial systems — at a granularity that generalist investors cannot match. The governance structure concentrates investment authority within the founding partnership, avoiding the committee drift that slows many larger Chinese venture platforms, while the firm’s independence from any single corporate or government parent preserves agility in deal execution.